143 related articles for article (PubMed ID: 36523718)
21. Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors.
Doz F; van Tilburg CM; Geoerger B; Højgaard M; Øra I; Boni V; Capra M; Chisholm J; Chung HC; DuBois SG; Gallego-Melcon S; Gerber NU; Goto H; Grilley-Olson JE; Hansford JR; Hong DS; Italiano A; Kang HJ; Nysom K; Thorwarth A; Stefanowicz J; Tahara M; Ziegler DS; Gavrilovic IT; Norenberg R; Dima L; De La Cuesta E; Laetsch TW; Drilon A; Perreault S
Neuro Oncol; 2022 Jun; 24(6):997-1007. PubMed ID: 34850167
[TBL] [Abstract][Full Text] [Related]
22. TRK Inhibitors: Clinical Development of Larotrectinib.
Bhangoo MS; Sigal D
Curr Oncol Rep; 2019 Feb; 21(2):14. PubMed ID: 30715603
[TBL] [Abstract][Full Text] [Related]
23. Dramatic response of STRN-NTRK-fused malignant glioneuronal tumor to larotrectinib in adult.
Boyer J; Birzu C; Bielle F; Goulas C; Savatovsky J; Karachi C; Idbaih A
Neuro Oncol; 2021 Jul; 23(7):1200-1202. PubMed ID: 34057471
[No Abstract] [Full Text] [Related]
24. Integrated genomic analysis reveals actionable targets in pediatric spinal cord low-grade gliomas.
Misove A; Vicha A; Broz P; Vanova K; Sumerauer D; Stolova L; Sramkova L; Koblizek M; Zamecnik J; Kyncl M; Holubova Z; Liby P; Taborsky J; Benes V; Pernikova I; Jones DTW; Sill M; Stancokova T; Krskova L; Zapotocky M
Acta Neuropathol Commun; 2022 Sep; 10(1):143. PubMed ID: 36163281
[TBL] [Abstract][Full Text] [Related]
25. NTRK-1 fusion in endocervical fibroblastic malignant peripheral nerve sheath tumor marking eligibility for larotrectinib therapy: A case report.
Wells AE; Mallen AM; Bui MM; Reed DR; Apte SM
Gynecol Oncol Rep; 2019 May; 28():141-144. PubMed ID: 31080864
[TBL] [Abstract][Full Text] [Related]
26. Larotrectinib Response in NTRK3 Fusion-Driven Diffuse High-Grade Glioma.
König D; Hench J; Frank S; Dima L; Bratic Hench I; Läubli H
Pharmacology; 2022; 107(7-8):433-438. PubMed ID: 35526519
[TBL] [Abstract][Full Text] [Related]
27. [Clinicopathological characteristics of H3K27-altered diffuse midline glioma and evaluation of NTRK as its therapeutic target].
Duan ZJ; Feng J; Yao K; Hu ZJ; Ma Z; Xiang L; Zhang XF; Qi XL
Zhonghua Bing Li Xue Za Zhi; 2022 Nov; 51(11):1115-1122. PubMed ID: 36323540
[No Abstract] [Full Text] [Related]
28. The 2021 WHO Classification of Tumors of the Central Nervous System: An update on pediatric low-grade gliomas and glioneuronal tumors.
Bale TA; Rosenblum MK
Brain Pathol; 2022 Jul; 32(4):e13060. PubMed ID: 35218102
[TBL] [Abstract][Full Text] [Related]
29. A newborn with a large NTRK fusion positive infantile fibrosarcoma successfully treated with larotrectinib.
Caldwell KJ; De La Cuesta E; Morin C; Pappo A; Helmig S
Pediatr Blood Cancer; 2020 Sep; 67(9):e28330. PubMed ID: 32452122
[TBL] [Abstract][Full Text] [Related]
30. Molecular-targeted therapy for childhood low-grade glial and glioneuronal tumors.
Siegel BI; Duke ES; Kilburn LB; Packer RJ
Childs Nerv Syst; 2024 Jun; ():. PubMed ID: 38877124
[TBL] [Abstract][Full Text] [Related]
31. Clinicopathological findings of pediatric NTRK fusion mesenchymal tumors.
Kang J; Park JW; Won JK; Bae JM; Koh J; Yim J; Yun H; Kim SK; Choi JY; Kang HJ; Kim WS; Shin JH; Park SH
Diagn Pathol; 2020 Sep; 15(1):114. PubMed ID: 32957984
[TBL] [Abstract][Full Text] [Related]
32. Successful treatment of lipofibromatosis-like neural tumor of the lumbar spine with an NTRK-fusion inhibitor.
Dupuis M; Shen Y; Curcio C; Meis JM; Wang WL; Amini B; Rhines L; Reuther J; Roy A; Fisher KE; Conley AP; Andrew Livingston J
Clin Sarcoma Res; 2020; 10():14. PubMed ID: 32782782
[TBL] [Abstract][Full Text] [Related]
33. [Clinicopathological characteristics of NTRK-rearranged mesenchymal tumors in childhood].
Yin MZ; Ma J; He Q; Shen P; Chen JF; Jin XT; Zhang ZD; Kuick CH; Chen HY; Ng EHQ; Aw SJ; Chang KTE
Zhonghua Bing Li Xue Za Zhi; 2020 Jul; 49(7):675-680. PubMed ID: 32610377
[No Abstract] [Full Text] [Related]
34. A Case of Inv(1)(q23q31)
Rekhi B; Shetty O; Bapat P; Gurav M; Qureshi S
Int J Surg Pathol; 2021 Feb; 29(1):102-108. PubMed ID: 32489127
[TBL] [Abstract][Full Text] [Related]
35. Case Report: Adult NTRK-Rearranged Spindle Cell Neoplasm: Early Tumor Shrinkage in a Case With Bone and Visceral Metastases Treated With Targeted Therapy.
Recine F; De Vita A; Fausti V; Pieri F; Bongiovanni A; Franchini E; Casadei R; Falasconi MC; Oboldi D; Matteucci F; Pallotti MC; Mercatali L; Riva N; Gurrieri L; Vanni S; Liverani C; Miserocchi G; Spadazzi C; Cocchi C; Ibrahim T
Front Oncol; 2021; 11():740676. PubMed ID: 35070960
[TBL] [Abstract][Full Text] [Related]
36. EWSR1-PATZ1 gene fusion may define a new glioneuronal tumor entity.
Siegfried A; Rousseau A; Maurage CA; Pericart S; Nicaise Y; Escudie F; Grand D; Delrieu A; Gomez-Brouchet A; Le Guellec S; Franchet C; Boetto S; Vinchon M; Sol JC; Roux FE; Rigau V; Bertozzi AI; Jones DTW; Figarella-Branger D; Uro-Coste E
Brain Pathol; 2019 Jan; 29(1):53-62. PubMed ID: 29679497
[TBL] [Abstract][Full Text] [Related]
37. [Diagnosis and therapy of tumors with NTRK gene fusion].
Stenzinger A; van Tilburg CM; Tabatabai G; Länger F; Graf N; Griesinger F; Heukamp LC; Hummel M; Klingebiel T; Hettmer S; Vokuhl C; Merkelbach-Bruse S; Overkamp F; Reichardt P; Scheer M; Weichert W; Westphalen CB; Bokemeyer C; Ivanyi P; Loges S; Schirmacher P; Wörmann B; Bielack S; Seufferlein TTW
Pathologe; 2021 Feb; 42(1):103-115. PubMed ID: 33258061
[TBL] [Abstract][Full Text] [Related]
38. Real-world survival outcomes in patients with locally advanced or metastatic NTRK fusion-positive solid tumors receiving standard-of-care therapies other than targeted TRK inhibitors.
Hibar DP; Demetri GD; Peters S; Davies J; Humblet O; Maund SL; Perez L
PLoS One; 2022; 17(8):e0270571. PubMed ID: 35939431
[TBL] [Abstract][Full Text] [Related]
39. Larotrectinib: A Targeted Therapy for Solid Tumors.
Mota-George G; Schneider SM
Clin J Oncol Nurs; 2021 Apr; 25(2):181-187. PubMed ID: 33739345
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
